CY1107616T1 - Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της - Google Patents
Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων τηςInfo
- Publication number
- CY1107616T1 CY1107616T1 CY20071100526T CY071100526T CY1107616T1 CY 1107616 T1 CY1107616 T1 CY 1107616T1 CY 20071100526 T CY20071100526 T CY 20071100526T CY 071100526 T CY071100526 T CY 071100526T CY 1107616 T1 CY1107616 T1 CY 1107616T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyridylmethylaminomethyl
- fluorophenyl
- physiologically acceptable
- chroman
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- HKFMQJUJWSFOLY-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-2-yl)-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNCC2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-UHFFFAOYSA-N 0.000 title 1
- HKFMQJUJWSFOLY-NRFANRHFSA-N 1-[(2s)-3,4-dihydro-2h-chromen-2-yl]-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-NRFANRHFSA-N 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 208000018300 basal ganglia disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118097 | 2001-07-26 | ||
| EP02790172A EP1408964B1 (en) | 2001-07-26 | 2002-07-10 | Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107616T1 true CY1107616T1 (el) | 2013-03-13 |
Family
ID=8178137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100526T CY1107616T1 (el) | 2001-07-26 | 2007-04-19 | Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7872030B2 (https=) |
| EP (1) | EP1408964B1 (https=) |
| JP (1) | JP2004538289A (https=) |
| KR (1) | KR20040029325A (https=) |
| CN (1) | CN1292749C (https=) |
| AR (1) | AR037496A1 (https=) |
| AT (1) | ATE352302T1 (https=) |
| AU (1) | AU2002355170B2 (https=) |
| BR (1) | BR0211358A (https=) |
| CA (1) | CA2455621C (https=) |
| CY (1) | CY1107616T1 (https=) |
| DE (1) | DE60217870T2 (https=) |
| DK (1) | DK1408964T3 (https=) |
| ES (1) | ES2280602T3 (https=) |
| HU (1) | HUP0402092A3 (https=) |
| MX (1) | MXPA04000775A (https=) |
| MY (1) | MY134059A (https=) |
| PE (1) | PE20030277A1 (https=) |
| PL (1) | PL208258B1 (https=) |
| PT (1) | PT1408964E (https=) |
| RU (1) | RU2297833C2 (https=) |
| SI (1) | SI1408964T1 (https=) |
| WO (1) | WO2003009835A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR058439A1 (es) | 2005-07-26 | 2008-02-06 | Portela & Ca Sa | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. |
| PT2161038E (pt) | 2006-01-26 | 2014-03-10 | Isis Pharmaceuticals Inc | Composições e suas utilizações dirigidas à huntingtina |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| EP2481410B1 (en) | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
| KR20110002462A (ko) | 2008-03-17 | 2011-01-07 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형 |
| AU2010231961B2 (en) | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| EP3626823A1 (en) * | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2013089573A1 (en) | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US576132A (en) * | 1897-02-02 | Current water-wheel | ||
| DE2364685C3 (de) | 1973-12-27 | 1978-06-15 | Beiersdorf Ag, 2000 Hamburg | Phenoxyäthylamine |
| US4438119A (en) * | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| CA1337429C (en) | 1983-12-05 | 1995-10-24 | Guy Rosalia Eugene Van Lommen | Derivatives of 2,2'-iminobisethanol |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| DE3901814A1 (de) | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| EP0465254B1 (en) | 1990-07-06 | 1996-11-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused thiophene compounds and uses thereof |
| DE4135474A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5314888A (en) | 1992-02-21 | 1994-05-24 | Trustees Of Tufts College | Veterinary method for treating inappropriate elimination of urine in household pets |
| SI9300097B (en) | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| AU3929493A (en) | 1992-03-11 | 1993-10-05 | Interneuron Pharmaceuticals, Inc. | Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa) |
| DE4226527A1 (de) | 1992-08-11 | 1994-02-17 | Merck Patent Gmbh | 1,4-Benzodioxanderivate |
| GB9302622D0 (en) | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
| CN1048247C (zh) * | 1994-01-31 | 2000-01-12 | 美国辉瑞有限公司 | 神经保护的苯并二氢吡喃化合物 |
| ZA954688B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | Serotonin 5-HT1A and dopamin D2 receptor ligands |
| PT707007E (pt) * | 1994-10-14 | 2002-06-28 | Merck Patent Gmbh | Derivados amino(tio)eter como agentes activos no snc |
| US5502080A (en) | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
| US5554383A (en) | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5541199A (en) | 1995-06-02 | 1996-07-30 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| AU6517196A (en) | 1995-07-13 | 1997-02-10 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| GB9514380D0 (en) | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| US5670667A (en) * | 1995-07-25 | 1997-09-23 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| US5756521A (en) * | 1996-04-03 | 1998-05-26 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| DE19648384A1 (de) | 1996-11-22 | 1998-05-28 | Merck Patent Gmbh | Fluorene, Dibenzofurane und Dibenzothiophene |
| EP0900792B1 (en) | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| DE69819266T2 (de) | 1997-09-02 | 2004-07-29 | Duphar International Research B.V. | Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| US6242456B1 (en) | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| CN1155567C (zh) | 1998-04-29 | 2004-06-30 | 惠氏公司 | 抑制精神的吲哚基衍生物 |
| UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
-
2002
- 2002-07-10 AU AU2002355170A patent/AU2002355170B2/en not_active Ceased
- 2002-07-10 AT AT02790172T patent/ATE352302T1/de active
- 2002-07-10 ES ES02790172T patent/ES2280602T3/es not_active Expired - Lifetime
- 2002-07-10 MX MXPA04000775A patent/MXPA04000775A/es active IP Right Grant
- 2002-07-10 KR KR10-2003-7016837A patent/KR20040029325A/ko not_active Ceased
- 2002-07-10 US US10/484,697 patent/US7872030B2/en not_active Expired - Fee Related
- 2002-07-10 BR BR0211358-9A patent/BR0211358A/pt not_active Application Discontinuation
- 2002-07-10 WO PCT/EP2002/007660 patent/WO2003009835A2/en not_active Ceased
- 2002-07-10 CA CA2455621A patent/CA2455621C/en not_active Expired - Fee Related
- 2002-07-10 EP EP02790172A patent/EP1408964B1/en not_active Expired - Lifetime
- 2002-07-10 DK DK02790172T patent/DK1408964T3/da active
- 2002-07-10 JP JP2003515228A patent/JP2004538289A/ja active Pending
- 2002-07-10 HU HU0402092A patent/HUP0402092A3/hu unknown
- 2002-07-10 DE DE60217870T patent/DE60217870T2/de not_active Expired - Lifetime
- 2002-07-10 RU RU2004105844/15A patent/RU2297833C2/ru not_active IP Right Cessation
- 2002-07-10 PT PT02790172T patent/PT1408964E/pt unknown
- 2002-07-10 CN CNB028146794A patent/CN1292749C/zh not_active Expired - Fee Related
- 2002-07-10 PL PL367291A patent/PL208258B1/pl not_active IP Right Cessation
- 2002-07-10 SI SI200230518T patent/SI1408964T1/sl unknown
- 2002-07-22 MY MYPI20022758A patent/MY134059A/en unknown
- 2002-07-24 PE PE2002000652A patent/PE20030277A1/es not_active Application Discontinuation
- 2002-07-26 AR ARP020102823A patent/AR037496A1/es unknown
-
2007
- 2007-04-19 CY CY20071100526T patent/CY1107616T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL367291A1 (en) | 2005-02-21 |
| HUP0402092A2 (hu) | 2005-02-28 |
| RU2297833C2 (ru) | 2007-04-27 |
| AR037496A1 (es) | 2004-11-17 |
| AU2002355170B2 (en) | 2007-06-07 |
| DE60217870D1 (de) | 2007-03-15 |
| DE60217870T2 (de) | 2007-11-15 |
| CN1535150A (zh) | 2004-10-06 |
| ES2280602T3 (es) | 2007-09-16 |
| MY134059A (en) | 2007-11-30 |
| KR20040029325A (ko) | 2004-04-06 |
| SI1408964T1 (sl) | 2007-06-30 |
| PT1408964E (pt) | 2007-05-31 |
| CA2455621C (en) | 2010-11-16 |
| WO2003009835A3 (en) | 2003-08-07 |
| DK1408964T3 (da) | 2007-05-21 |
| WO2003009835A2 (en) | 2003-02-06 |
| MXPA04000775A (es) | 2004-04-20 |
| US20040171645A1 (en) | 2004-09-02 |
| RU2004105844A (ru) | 2005-05-10 |
| PL208258B1 (pl) | 2011-04-29 |
| PE20030277A1 (es) | 2003-03-25 |
| CN1292749C (zh) | 2007-01-03 |
| BR0211358A (pt) | 2004-09-21 |
| US7872030B2 (en) | 2011-01-18 |
| EP1408964B1 (en) | 2007-01-24 |
| JP2004538289A (ja) | 2004-12-24 |
| ATE352302T1 (de) | 2007-02-15 |
| HK1068793A1 (en) | 2005-07-29 |
| EP1408964A2 (en) | 2004-04-21 |
| HUP0402092A3 (en) | 2010-06-28 |
| CA2455621A1 (en) | 2003-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107616T1 (el) | Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της | |
| CY1109472T1 (el) | Χρηση της 1-4(5-κυανοϊνδολ-3-υλο)βουτυλο-4-(2-καρβαμοϋλοβενζοφουραν-5-υλο)πιπεραζινης και των φυσιολογικα αποδεκτων αλατων αυτης | |
| GB0117645D0 (en) | Therapeutic stratergies for prevention and treatment of alzheimers disease | |
| EE02971B1 (et) | Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks | |
| BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| ATE506058T1 (de) | Pharmazeutisch aktive isoindolin-derivate | |
| EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
| EA200101156A1 (ru) | ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ | |
| DE60327089D1 (de) | Systeme zum verschieben und/oder zurückhalten von gewebe in den oberen atemwegen | |
| CY1110712T1 (el) | Χρηση ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδης στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1113312T1 (el) | Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων | |
| HRP20040352B1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| HUP0301380A2 (hu) | Roszuvasztatin (ZD-4522) felhasználása heterozigóta örökletes hiperkoleszterolémia kezelésére alkalmas gyógyszerkészítmény előállítására | |
| CY1107383T1 (el) | Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος | |
| CY1109013T1 (el) | Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν | |
| DK0981347T3 (da) | Anvendelsen af levobupivacain i ansigtkirurgi | |
| ATE410148T1 (de) | Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten | |
| CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
| PL356428A1 (en) | Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
| CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
| HUP0402654A2 (hu) | 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| BR0312511A (pt) | 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos | |
| SE9602262D0 (sv) | New use of derivatives of cystine | |
| DE50313136D1 (de) | Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben | |
| CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος |